Analgesic effects of human placental hydrolysate on capsaicin-induced hyperalgesia in rats Authors: Baoji Lu, Tae Woo Kim, Eun-ee Jung, Guanghai Nan, Jae-Won Kim, Kyeongsoo Jeong, Minju Im, SoHyun Jeon, Hee Young Kim, Tae Hwan Cho, Seungsoo Chung, Dong Ah Shin Published: 2026 ABSTRACT To explore the analgesic potential of HPH, we examined whether HPH could reduce primary and secondary hyperalgesia in a rat model of capsaicin-induced pain and whether co-administration with dexamethasone could provide enhanced analgesia with fewer side effects. HPH was administered in capsaicin-induced pain model. Primary and secondary hyperalgesia were assessed using von Frey filaments. Voltage-sensitive dye imaging (VSDI) was conducted in spinal cord slices to examine neuronal excitability. Immunohistochemistry was performed to evaluate c-Fos and phosphorylated PKCε (p-PKCε) expression. Body weight was monitored as an indicator of corticosteroid-associated side effects in rats treated with dexamethasone alone or in combination with HPH. HPH dose-dependently attenuated capsaicin-induced both primary and secondary hyperalgesia, suppressed spinal dorsal horn hyperactivity, and reduced expression of c-Fos and p-PKCε. Combination of HPH with low-dose dexamethasone produced analgesia comparable to high-dose dexamethasone while reducing corticosteroid-related weight loss, as reflected by body weight loss. HPH effectively alleviated capsaicin-induced neurogenic inflammatory pain and enhanced the therapeutic profile of dexamethasone. Co-treatment with low-dose dexamethasone may provide synergistic analgesic benefits while minimizing side effect, supporting HPH as a promising adjunctive therapy for corticosteroid-based pain management. Introduction Pain, especially inflammatory pain, represents a major clinical challenge worldwide, affecting up to 20% of the global population and imposing substantial personal and socioeconomic burdens1,2. Such pain conditions often lead to disability, reduced quality of life, and high healthcare costs3,4. Corticosteroids are widely prescribed for their potent anti-inflammatory and analgesic properties and remain a mainstay in the management of pain associated with inflammation5,6. However, their long-term use is restricted by serious side effects, including metabolic disturbances7, osteoporosis8, and immune suppression9, which limit their clinical utility. These limitations underscore the need for adjunctive strategies that preserve therapeutic efficacy while reducing systemic toxicity. Human placental hydrolysate (HPH) contains a complex mixture of biologically active substances, including amino acids, peptides, nucleotides10 that contribute to pharmacological effects. The antioxidant and anti-inflammatory effects of HPH are relatively well known in inflammatory conditions, especially in liver diseases, based on findings from both experimental and clinical studies11–15. In the patients with osteoarthritis, HPH has also been clinically applied to alleviate pain symptoms16,17. While some clinical studies have shown promise in the treatment of pain conditions like osteoarthritis, shoulder impingement syndrome and chronic back pain16–18, the mechanism underlying analgesic effect of HPH remains unclear. Capsaicin, the pungent compound in chili peppers, induces pain by activating transient receptor potential vanilloid 1 (TRPV1) channel on nociceptive fibers, producing a burning sensation and local inflammation. Intradermal injection of capsaicin results in primary hyperalgesia at the site of application, characterized by increased sensitivity to thermal and mechanical stimuli due to peripheral sensitization of nociceptors. Secondary hyperalgesia also develops in surrounding uninjured areas and reflects central sensitization, leading primarily to enhanced mechanical sensitivity. This model is particularly useful for determining whether the analgesic effects of compound are mediated through peripheral or central site of action19. In this context, previous in vitro and animal studies provide mechanistic evidence supporting the potential of HPH in alleviating pain14,20–22. Specifically, HPH significantly attenuated inflammatory pain behaviors and reduced pro-inflammatory cytokine expression (TNF-α, IL-1β, IL-6) in a complete Freund’s adjuvant (CFA)-induced inflammatory pain model in mice21, implicating its ability to modulate pathways involved in nociceptive sensitization. Additionally, HPH suppressed inflammatory responses in a dinitrochlorobenzene (DNCB)-induced atopic dermatitis mouse model and reduced cytokine levels, further supporting its anti-inflammatory and neuro-modulatory potentials22. Collectively, these preclinical findings provide a mechanistic rationale for investigating whether HPH can attenuate pain underlying capsaicin-induced hyperalgesia, which is driven by peripheral inflammatory sensitization. The present study investigated whether HPH could alleviate capsaicin-induced primary hyperalgesia and secondary hyperalgesia and compared its efficacy with dexamethasone, a standard corticosteroid used for pain relief23 but limited by systemic side effects24,25. Furthermore, we examined whether combining HPH with a low dose of dexamethasone could provide a synergistic analgesic effect while reducing corticosteroid-associated adverse outcomes such as body weight loss. Behavioral assessments and molecular analyses were performed to explore potential mechanisms underlying the analgesic effects of HPH. Materials and methods Chemicals Capsaicin (M2028; Sigma-Aldrich, St. Louis, MO, USA), olive oil (O1514; Sigma-Aldrich, St. Louis, MO, USA), dexamethasone disodium phosphate (08806505003025; Jeil Pharmaceutical Co., Ltd., Daegu, Korea), and human placental hydrolysate (HPH; Laennec®, GC Wellbeing, Seoul, Korea) were used. Experimental animals Adult male Sprague–Dawley rats (8 weeks; 250–300 g; Orient Bio, Sungnam, Gyonggi, Korea) were used. The rats were housed in groups of three in plastic cages with soft bedding under a 12-h light/dark cycle with free access to food and water. All experimental procedures involving animals were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of Yonsei University Health System (permit no.: 2024–0001). Capsaicin-induced pain model The procedure for capsaicin injection in rats was performed as described previously26. Briefly, rats were lightly anesthetized with isoflurane (Kyongbo Pharmaceutical CO., LTD, Asan, Republic of Korea), and a 30-gauge needle (with a Hamilton syringe) was inserted through the skin at the heel (designated as site X in Fig. 1A) and advanced to the central plantar area of the left hind paw (site I), which was used consistently across all experiments. At this location, capsaicin (20 μg in 20 μl of olive oil) was administered via intradermal injection slowly. After the procedure, rats were returned to their home cage and closely observed until they recovered fully from anesthesia (typically within 5 min). Fig. 1Analgesic effect of human placental hydrolysate (HPH) in a capsaicin-induced pain model. (A) Schematic representation of pain induction. Capsaicin (CAP; 20 μg in 20 μL olive oil) was injected intradermally into the left hind paw. The needle was inserted at the heel (site X) and advanced to the injection site (site I). Mechanical sensitivity was assessed at two distinct sites: the primary hyperalgesia site (P), and the secondary hyperalgesia site (S). (B) Experimental timeline for drug administration and von Frey filament behavioral test (BT). (C, D) Effects of different concentrations of HPH on capsaicin-induced primary (C) and secondary (D) hyperalgesia (n = 6 in CAP-Veh group; n = 5 in CAP-HPH 1.8 mL/kg group; n = 6 in CAP-HPH 3.6 mL/kg group). **p < 0.01, *p < 0.05 vs. CAP-Veh group, ##p < 0.01 vs. −0.5 h, two-way repeated ANOVA followed by Tukey’s post hoc test. Analgesic effect of human placental hydrolysate (HPH) in a capsaicin-induced pain model. (A) Schematic representation of pain induction. Capsaicin (CAP; 20 μg in 20 μL olive oil) was injected intradermally into the left hind paw. The needle was inserted at the heel (site X) and advanced to the injection site (site I). Mechanical sensitivity was assessed at two distinct sites: the primary hyperalgesia site (P), and the secondary hyperalgesia site (S). (B) Experimental timeline for drug administration and von Frey filament behavioral test (BT). (C, D) Effects of different concentrations of HPH on capsaicin-induced primary (C) and secondary (D) hyperalgesia (n = 6 in CAP-Veh group; n = 5 in CAP-HPH 1.8 mL/kg group; n = 6 in CAP-HPH 3.6 mL/kg group). **p < 0.01, *p < 0.05 vs. CAP-Veh group, ##p < 0.01 vs. −0.5 h, two-way repeated ANOVA followed by Tukey’s post hoc test. Drug administration Two different doses of HPH were chosen and administered intraperitoneally: 3.6 mL/kg as the reference therapeutic dose and 1.8 mL/kg as a half-dose to evaluate dose dependency, based on previous studies27,28. Dexamethasone was administered intraperitoneally at 1 mg/kg (low dose) or 5 mg/kg (high dose). Saline was used as the control. Behavioral assessment of capsaicin-induced pain As previously described26, mechanical hypersensitivity was assessed using the up-down method with a series of von Frey filaments (Stoelting, Chicago, IL, USA) applied to the injection site to evaluate primary hyperalgesia and to an adjacent area to evaluate secondary hyperalgesia. Baseline assessment was performed at 0.5 h before HPH application (−0.5 h). Following capsaicin injection (0 h), behavioral test was conducted at 0.5, 1, 1.5, 2, and 24 h post-injection. The 50% mechanical withdrawal threshold (MWT) was calculated, and all behavioral test was conducted in a blinded manner. Voltage sensitive dye imaging (VSDI) in spinal dorsal horns Voltage sensitive dye imaging (VSDI) was carried out as performed in our laboratory29. In brief, rats were deeply anesthetized with urethan (1.25 g/kg, intraperitoneally) after 30 min of capsaicin injection and transcardially perfused with ice-cold solution containing 213 mM sucrose, 2.5 mM KCl, 1.25 mM NaH₂PO₄, 10 mM MgSO₄, 0.5 mM CaCl₂, 26 mM NaHCO₃, and 11 mM glucose. The L4-L5 spinal cord segments were surgically extracted and immediately immersed in ice-cold artificial cerebrospinal fluid (aCSF) solution for 5 min. The spinal cord was mounted on an agarose block and sectioned into 400-μm thick transverse slices using a vibratome (Leica Biosystems Inc., Buffalo Grove, IL, USA). These sections were immediately placed in interface chambers perfused with oxygenated aCSF containing: 126 mM NaCl, 2.5 mM KCl, 1.25 mM NaH₂PO₄, 2 mM MgCl₂, 2 mM CaCl₂, 26 mM NaHCO₃, and 10 mM glucose, continuously bubbled with 95% O₂/5% CO₂ to maintain pH 7.2. After a 1 h recovery period at room temperature under continuous aCSF perfusion, sections were incubated for 1 h with voltage-sensitive dye (di-2-ANEPEQ, 50 μg/mL in aCSF; Molecular Probes, Eugene, OR, USA). For optical recordings, a concentric bipolar microelectrode (30213, FHC, Bowdoin, Maine, USA) was positioned within the region of dorsal horn (laminae I–II) using an optical microscope (Olympus Optical Co. Ltd., Tokyo, Japan) equipped with a 10 × objective and 0.35 × projection lens. Electrical stimulation consisted of square pulses (2 ms duration, 5-second interstimulus interval) delivered through a stimulus isolation unit (World Precision Instruments, Sarasota, FL, USA), with intensity adjusted to evoke reliable responses. Neuronal activity was captured using a high-resolution CCD camera-based optical imaging system (Brainvision Inc., Tokyo, Japan) configured with a dichroic mirror, 510–555 nm excitation filter, and 590 nm emission filter. A 150 W tungsten-halogen lamp provided fluorescence excitation. The imaging field encompassed 184 × 124 pixels. Fluorescence measurements were acquired over 943.5 ms periods using the MiCAM02 optical imaging device (Brainvision Inc.) at a temporal resolution of 3.7 ms per frame. Signals were averaged over 20 trials to improve signal-to-noise ratio. Fluorescence changes were normalized by calculating the fractional change (ΔF/F) relative to baseline fluorescence for each pixel. Signal amplitude and spatial extent of activation were analyzed using spatial filtering (9 × 9 pixels) and cubic filtering (3 × 3 pixels). After the baseline responses were recorded, the slice was either maintained in aCSF (vehicle) or treated with HPH. For HPH treatment in vitro, lyophilized HPH was dissolved in aCSF and transferred into the chamber. The slice was incubated with HPH for 30 min. Following incubation, the same electrical stimulation protocol (0.3, 0.6, 0.9 mA) was applied, and the post-treatment VSD responses were recorded. All data acquisition and analysis were performed using BV Analyzer software (Brainvision Inc.). Optical signals were quantified as percentage fluorescence change (%ΔF/F) within circular areas (radius = 5 pixels) positioned specifically in the dorsal horn region. Both temporal dynamics and spatial patterns of activation were systematically analyzed. Immunohistochemistry for c-Fos or PKC expression in spinal dorsal horns As performed in our laboratory29, rats were deeply anesthetized with sodium pentobarbital (50 mg/kg, intraperitoneally) 30 min after intradermal capsaicin injection and perfused with 150 mL of 0.01 M phosphate-buffered saline (PBS, pH 7.4), followed by 500 mL of 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The L5 spinal cord segment was dissected out and post-fixed in 4% paraformaldehyde for 2 h at 4 °C, then cryoprotected in 30% sucrose solution for 12 h at 4 °C. Tissue Sects. (40 μm thickness) were prepared using a freezing microtome (Cryostat 1720; Leitz, Mannheim, Germany). Free-floating sections were washed three times in 0.01 M PBS before blocking for 1 h at room temperature with 10% normal goat serum (ab7481; Abcam, Cambridge, MA) or donkey serum (ab7475; Abcam) in PBS containing 0.3% Triton X-100. For c-Fos labeling, primary antibody incubation was performed at room temperature using rabbit anti-Fos antibody (1:1000, ab190289; Abcam). Following three-time PBS washes, sections were incubated for 2 h at room temperature with Alexa Fluor 488-conjugated goat anti-rabbit IgG secondary antibody (1:200; AB_2576217; Invitrogen, Thermo Fisher Scientific, Waltham, MA) in 0.3% Triton X-100 PBS solution. For phosphorylated protein kinase C (P-PKC) staining, a similar protocol was followed on separate sections: a goat monoclonal anti-phospho-PKC (p-PKCε (Ser 729): sc-12355, 1:500, Santa Cruz Biotechnology, Dallas, TX) was used as primary, and an Alexa Fluor 647–conjugated donkey anti-goat IgG (AB_2535864; Invitrogen) as secondary. In all cases, nuclei were counterstained with DAPI (4′,6-diamidino-2-phenylindole, blue fluorescence, Sigma-Aldrich, St. Louis, MO 63103 USA) before mounting the sections. Finally, sections were mounted onto glass slides and cover slipped with an anti-fade mounting medium. Immunofluorescence imaging was performed using a Zeiss LSM 710 confocal laser scanning microscope (Axio Examiner.Z1, Jena, Germany). For each rat, multiple sections of the L5 dorsal horn were imaged, and the number of c-Fos–positive nuclei was counted in a standardized region of the superficial dorsal horn (laminae I–III) on the side of capsaicin injection. P-PKCε immunoreactivity was quantified by calculating the percentage of neurons (identified by DAPI-stained nuclei) that showed clear PKC phosphorylation (red cytoplasmic staining) in the dorsal horn. Quantification was performed using ImageJ (National Institutes of Health, Bethesda, MD, USA). Statistical analysis All statistical analyses were conducted using GraphPad Prism 9.0 (GraphPad Software Inc., San Diego, CA, USA). Behavioral and body weight data were analyzed by two-way analysis of variance (ANOVA), followed by Tukey’s multiple comparisons test. Optical signal intensities were compared by two-way ANOVA, followed by Bonferroni’s post hoc test. Immunohistochemistry data were analyzed using one-way ANOVA followed by Tukey’s post hoc test. Data are presented as means ± standard error of the mean (SEM). P values less than 0.05 were considered statistically significant. Result HPH alleviates capsaicin-induced hyperalgesia in a dose-dependent manner To evaluate the analgesic effect of HPH in the capsaicin-induced pain model, capsaicin was injected into X site and primary hyperalgesia at the injection site (site P) and secondary hyperalgesia at the base of the third-fourth toes (site S) were measured (Fig. 1A). Rats were randomly assigned to three groups: (1) CAP-Veh (capsaicin + saline), (2) CAP-HPH 1.8 mL/kg (capsaicin + HPH 1.8 mL/kg), (3) CAP-HPH 3.6 mL/kg (capsaicin + HPH 3.6 mL/kg). HPH was administered 0.5 h before capsaicin injection. Behavioral tests were performed at 0.5 h before capsaicin injection and 0.5, 1, 1.5, 2 and 24 h after capsaicin injection (Fig. 1B). Thirty minutes after intradermal injection of capsaicin, the mean paw withdrawal threshold (MWT) rapidly dropped from a pre-injection value (log value = 5.1) of approximately 12 g to around 1 g (CAP-Veh) (p < 0.01; for time: F5, 84 = 17.85, p < 0.0001; for group: F2, 84 = 14.01, p < 0.0001; for time × group: F 10, 84 = 0.7767, p = 0.6508, Fig. 1C), indicating development of primary hyperalgesia by intradermal capsaicin. This reduction remained statistically significant for about 2 h (p < 0.0001), followed by a gradual recovery over 24 h. Intraperitoneal administration of HPH attenuated capsaicin-induced changes of MWTs at both primary and secondary sites in a dose-dependent manner, compared to the CAP-Veh group. CAP-HPH (3.6 mL/kg) group significantly reduced primary hyperalgesia at 1 and 2 h after capsaicin injection (p < 0.01, Fig. 1C) and suppressed secondary hyperalgesia up to 24 h (Fig. 1D) compared with the vehicle (p < 0.05). It showed that HPH, particularly at 3.6 mL/kg, effectively attenuated both primary and secondary hyperalgesia induced by capsaicin, with significant analgesic effects evident from 1 h and persisting up to 24 h. HPH reduces neuronal activity in the spinal cord dorsal horn of the capsaicin-induced pain model To investigate the effect of HPH on the neuronal excitability of spinal dorsal horns, VSDI was performed on spinal cord slices from capsaicin-injected rats. Animals were divided into Veh and HPH groups. Neuronal activity was recorded before and during vehicle or HPH treatment. Based on the previous study30, the electrical stimulation intensities of 0.3, 0.6, 0.9 mA were applied. Neuronal signals and the activated areas increased in a stimulation intensity-dependent manner (Fig. 2A). As the baseline (Pre) amplitudes appeared to differ between the Veh and HPH groups, we performed an additional comparisons of Pre values at each stimulation intensity. No significant differences were observed at any stimulation intensity (p > 0.05). While no significant differences were observed between the pre- and vehicle treatment phases at any stimulation intensity in the Veh group (Fig. 2B). On the other hand, HPH treatment reduced stimulation-induced peak amplitudes at 0.9 mA compared with the values before HPH treatment (p < 0.01; for phase: F2, 24 = 19.84, p < 0.0001; for group: F1, 24 = 14.82, p = 0.0008; for phase × time: F2, 24 = 0.7181, p = 0.4979; Fig. 2C). These results indicate that HPH effectively reduced the neuronal excitability of spinal dorsal horns following intra-plantar injection of capsaicin. Fig. 2Changes in neuronal activity in the spinal dorsal horn of the capsaicin-induced pain model following HPH treatment. (A) Representative image showing electrical stimulation intensity-dependent neuronal activity in the spinal dorsal horn following HPH or vehicle treatment. (B, C) Comparison of peak amplitudes before and during the treatment of vehicle (B) or HPH (C) (n = 5 per group). (D) Comparison of pretreatment baseline amplitudes between the Vehicle and HPH groups. *P < 0.05 vs. vehicle group, two-way repeated ANOVA followed by Bonferroni’s post hoc test. Changes in neuronal activity in the spinal dorsal horn of the capsaicin-induced pain model following HPH treatment. (A) Representative image showing electrical stimulation intensity-dependent neuronal activity in the spinal dorsal horn following HPH or vehicle treatment. (B, C) Comparison of peak amplitudes before and during the treatment of vehicle (B) or HPH (C) (n = 5 per group). (D) Comparison of pretreatment baseline amplitudes between the Vehicle and HPH groups. *P < 0.05 vs. vehicle group, two-way repeated ANOVA followed by Bonferroni’s post hoc test. HPH attenuates capsaicin-induced both c-Fos expression and p-PKCε immunoreactivity in spinal dorsal horn Expression of c-Fos (a marker of neuronal activation) and p-PKCε (a signaling mediator implicated in nociceptive sensitization) in the spinal dorsal horn was estimated to investigate the analgesic mechanism of HPH in capsaicin-induced pain model. Experiment was performed in the following groups: (1) Naive (no intradermal capsaicin injection); (2) CAP-Veh (intraperitoneal saline prior to capsaicin injection); (3) CAP-HPH (intraperitoneal HPH at 3.6 mL/kg before capsaicin injection). Either saline or HPH was administered 30 min before capsaicin injection. Capsaicin injection increased the number of c-Fos positive nuclei in the superficial dorsal horn (CAP-Veh group) compared to naive group (p < 0.01; F2, 13 = 7.03, p = 0.0085), whereas this increase was prevented by HPH treatment (CAP-HPH vs. naive group, p < 0.05, Fig. 3A, B). Similarly, significantly enhanced expression of p-PKCε was observed in the capsaicin-induced pain model compared with naive group (p < 0.01, F2, 8 = 8.725, p = 0.0098), which was attenuated by HPH pretreatment (p < 0.05, Fig. 3C, D). These results indicate that HPH mitigated both neuronal activation and PKCε phosphorylation in the spinal dorsal horn following capsaicin injection. Fig. 3Changes in pain-related molecular markers in the rat spinal cord following HPH treatment. (A) Representative immunofluorescence images of c-Fos expression in the spinal dorsal horn. (B) Comparison of c-Fos positive cells in the spinal dorsal horn among the groups (n = 4 in Naïve group, n = 6 in CAP-Veh and CAP-HPH groups). (C) Representative immunofluorescence images of p-PKC expression in the spinal dorsal horn. (D) Comparison of p-PKC area positive cells in the spinal dorsal horn among the groups (n = 5 in Naïve group, n = 3 in CAP-Veh and CAP-HPH groups). **P < 0.01, *p < 0.05, one-way ANOVA followed by Tukey’s post hoc test. Changes in pain-related molecular markers in the rat spinal cord following HPH treatment. (A) Representative immunofluorescence images of c-Fos expression in the spinal dorsal horn. (B) Comparison of c-Fos positive cells in the spinal dorsal horn among the groups (n = 4 in Naïve group, n = 6 in CAP-Veh and CAP-HPH groups). (C) Representative immunofluorescence images of p-PKC expression in the spinal dorsal horn. (D) Comparison of p-PKC area positive cells in the spinal dorsal horn among the groups (n = 5 in Naïve group, n = 3 in CAP-Veh and CAP-HPH groups). **P < 0.01, *p < 0.05, one-way ANOVA followed by Tukey’s post hoc test. HPH-dexamethasone combination achieves analgesia comparable to high-dose dexamethasone in the capsaicin-induced pain model To investigate whether combined administration could reduce the requirement for high-dose dexamethasone (5 mg/kg), multiple treatment groups were established, and primary and secondary hyperalgesia were measured separately. To evaluate the effect of HPH alone, HPH combined with dexamethasone (DEX) or DEX alone, rats were divided into five groups: (1) CAP-Veh (capsaicin + saline), (2) CAP-HPH 3.6 mL/kg (capsaicin + HPH 3.6 mL/kg), (3) CAP-DEX 1 mg/kg (capsaicin + low dose dexamethasone (1 mg/kg)), (4) CAP-DEX 5 mg/kg (capsaicin + high dose dexamethasone (5 mg/kg)), and (5) CAP-DEX 1 mg/kg + HPH (capsaicin + dexamethasone 1 mg/kg + HPH 3.6 mL/kg). DEX and/or HPH were administered 30 min before capsaicin injection. Behavioral tests were conducted at 0.5 h before capsaicin (−0.5 h) and 0.5, 1, 1.5, 2 and 24 h after capsaicin injection. While capsaicin injection lowered MWTs compared to the value before capsaicin (p < 0.0001), pretreatment with dexamethasone at a high dose of 5 mg/kg significantly alleviated primary hyperalgesia in capsaicin-injected rats (CAP-DEX 5 mg/kg) compared to control group (Fig. 4A; CAP-Veh; p < 0.05 at 2 h; for time: F5, 198 = 36.45, p < 0.0001; for group: F4, 198 = 6.269, p < 0.0001; for time × group: F20, 198 = 0.8970, p = 0.5913). However, administration of dexamethasone at a lower dose of 1 mg/kg failed to inhibit primary and secondary hyperalgesia (Fig. 4A, B). On the other hand, HPH monotherapy also attenuated primary and secondary hyperalgesia, and co-treatment of a low dose dexamethasone (1 mg/kg) with HPH produced a more pronounced early analgesic effect, particularly at 0.5 and 1 h after capsaicin injection. At later time points, however, the recovery pattern of the combination group was broadly comparable to that of the HPH-alone group. These findings suggest that treatment of HPH combined with a low dose dexamethasone produced similar analgesic effects as high-dose dexamethasone. Fig. 4Analgesic effect of dexamethasone with or without HPH in the capsaicin-induced pain model. (A, B) Effects of HPH alone, different concentrations of dexamethasone and combined treatment (HPH + dexamethasone 1 mg/kg) applied to the hind paw on capsaicin-induced primary (A) and secondary (B) hyperalgesia (n = 6 in HPH alone group, n = 8 in other groups). **P < 0.01, *p < 0.05 vs. CAP-Veh group, two-way repeated ANOVA followed by Bonferroni’s post hoc test. Analgesic effect of dexamethasone with or without HPH in the capsaicin-induced pain model. (A, B) Effects of HPH alone, different concentrations of dexamethasone and combined treatment (HPH + dexamethasone 1 mg/kg) applied to the hind paw on capsaicin-induced primary (A) and secondary (B) hyperalgesia (n = 6 in HPH alone group, n = 8 in other groups). **P < 0.01, *p < 0.05 vs. CAP-Veh group, two-way repeated ANOVA followed by Bonferroni’s post hoc test. HPH co-administration mitigates dexamethasone-induced body weight loss To see potential systemic side effects of HPH and/or dexamethasone, rats were divided into five groups: (1) Saline, (2) HPH 3.6 mL/kg, (3) DEX 1 mg/kg, (4) DEX 5 mg/kg, (5) HPH 3.6 mL/kg + DEX 1 mg/kg. Animals received once-daily intraperitoneal injections of the assigned treatment for five consecutive days (Day 0–4), followed by two drug-free days (Days 5–6). Body weight was recorded at baseline (prior to the first injection), daily before each injection, and again on Day 7 (72 h after the last dose) to assess recovery (Fig. 5A). HPH (3.6 mL/kg) group showed a steady increase in body weight over the observation period, consistent with vehicle-treated group (Saline). It is noted that dexamethasone treatment at either 5 mg/kg or 1 mg/kg caused profound body weight losses from Day 2, reaching ~ 88% of baseline by Day 4 (p < 0.0001; for day: F5, 150 = 29.18, p < 0.0001; for group: F4, 150 = 98.69, p < 0.0001; for day × group: F20, 150 = 13.59, p < 0.0001). Even after two drug-free days, body weight remained below 90% of baseline on Day 7 compared with the Saline group. Although rats receiving combined treatment of HPH and dexamethasone treatment also exhibited weight loss during the dosing phase, the body weight partially recovered after drug discontinuation, reaching ~ 95% of baseline by Day 7, in contrast to the persistent loss observed with dexamethasone alone. These results indicate that dexamethasone induces pronounced body weight loss as a systemic side effect, while cotreatment with HPH partially mitigates this catabolic effect. Fig. 5Changes of body weight following repeated dexamethasone or combined HPH and dexamethasone treatment. (A) Experimental timeline for drug treatment and the measurement of body weight. (B) Body weight changes over time following treatment (n = 6 per group). ****P < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05 vs. Saline group, as determined using two-way repeated ANOVA followed by Tukey’s post hoc test. Changes of body weight following repeated dexamethasone or combined HPH and dexamethasone treatment. (A) Experimental timeline for drug treatment and the measurement of body weight. (B) Body weight changes over time following treatment (n = 6 per group). ****P < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05 vs. Saline group, as determined using two-way repeated ANOVA followed by Tukey’s post hoc test. Discussion The present study demonstrates the analgesic effect of human placental hydrolysate (HPH) in a capsaicin-induced pain model. Pretreatment with HPH effectively alleviated both primary and secondary hyperalgesia and suppressed neuronal activity by inhibiting PKCε activation. Moreover, combined administration of HPH with dexamethasone produced a comparable antinociceptive effect while permitting a reduced dose of dexamethasone and attenuating dexamethasone-induced body weight loss. These results suggest that HPH can suppress capsaicin-induced primary and secondary hyperalgesia while minimizing the adverse effects of dexamethasone monotherapy. The analgesic efficacy of HPH was evaluated in capsaicin-induced pain model. The capsaicin-induced pain model represents an acute form of inflammatory and neurogenic pain31, as capsaicin activates TRPV1 receptors on primary sensory neurons, leading to neurogenic inflammation, peripheral sensitization32, and subsequent central sensitization33. In this model, pretreatment with HPH effectively alleviated both primary and secondary hyperalgesia. Since primary hyperalgesia reflects peripheral sensitization at the site of injury, whereas secondary hyperalgesia reflects spinal cord and beyond, the ability of HPH to suppress both types of hyperalgesia suggests that it may exert dual actions on peripheral nociceptor activity and central pain processing. HPH contains various bioactive components, including peptides and amino acids, which exert anti-inflammatory, antioxidant, and tissue-protective effects13,17. As the bioactive components of HPH generated the analgesic efficacy observed in this study, identifying the specific components responsible for the analgesic effect will be an important subject of future investigation. Given that HPH alleviated secondary hyperalgesia at the behavioral level, we next examined spinal cord excitability using VSDI to determine whether these effects were associated with changes in dorsal horn neuronal activity. The reduction of neuronal responses following HPH treatment suggests that HPH dampens stimulus-evoked hyperexcitability within the dorsal horn, a hallmark of central sensitization34,35. Although VSDI does not resolve single-cell activity, its strength lies in capturing spatiotemporal patterns of neuronal population dynamics, thereby providing network-level evidence for the central actions of HPH. Together, these findings support the notion that HPH exerts its analgesic effects not only through peripheral modulation but also by influencing spinal pain circuitry, consistent with previous reports highlighting the importance of reducing dorsal horn hyperactivity in inflammatory pain36,37. IHC analyses further supported the central actions of HPH by demonstrating reductions in c-Fos and PKC expression in the spinal dorsal horn. c-Fos is widely recognized as a marker of neuronal activation in pain research38, and studies have shown its robust upregulation in the dorsal horn following inflammatory or capsaicin-induced pain39, reflecting enhanced nociceptive input and central sensitization40. In line with these observations, the suppression of c-Fos expression by HPH in our study suggests that the treatment attenuates excessive neuronal activation under acute inflammatory pain conditions. Similarly, PKC, particularly the PKCε isoform, has been implicated in excitatory synaptic plasticity41 and the maintenance of central sensitization through the phosphorylation and trafficking of AMPA42 and NMDA receptors43. Previous studies have reported that enhanced PKC activity in inflammatory and neuropathic pain models, contributing to spinal hyperexcitability44,45. Our finding that HPH reduced PKC expression therefore indicates that inhibition of PKC-dependent signaling may represent a key mechanism by which HPH counteracts spinal hyperexcitability. Together, these results suggest that HPH suppressed secondary hyperalgesia by inhibiting PKC-dependent signaling and central sensitization in spinal dorsal horn neurons. Because the clinical use of dexamethasone is limited by dose-dependent adverse effects46,47, we investigated whether combining HPH with dexamethasone could provide effective analgesia while minimizing corticosteroid exposure. In the capsaicin-induced pain model, our results showed that combining HPH with dexamethasone produced a more pronounced early analgesic effect than HPH alone, particularly at 0.5 and 1 h after capsaicin injection and achieved analgesic effects equivalent to high-dose dexamethasone, but with a reduced corticosteroid requirement. At the primary site, the combination achieved efficacy similar to 5 mg/kg dexamethasone, whereas at the secondary site the analgesic effect appeared more sustained. The comparable effect at the primary site likely reflects the strong anti-inflammatory action of dexamethasone in suppressing peripheral sensitization48, which is mainly driven by TRPV1 activation and the release of inflammatory mediators49. In contrast, the more prolonged effect at the secondary site may indicate that HPH provides additional modulatory actions relevant to central pain processing, thereby complementing the effects of dexamethasone. Importantly, this combination strategy also offers a pharmacological advantage by reducing the glucocorticoid burden. Corticosteroid-related adverse effects, including metabolic disturbances, osteoporosis, immunosuppression, and alterations in body weight, are well recognized to be dose- and duration-dependent24,50. This concept is consistent with the principles of multimodal analgesia, in which combining agents with distinct but complementary mechanisms enhanced therapeutic benefit while minimizing side effects51. Such a strategy could be particularly valuable in clinical contexts requiring repeated or prolonged corticosteroid administration, where the cumulative risk of side effects poses a major limitation. To further evaluate systemic tolerability, we examined body weight changes as a representative adverse effect. In normal rats without capsaicin treatment, repeated dexamethasone administration resulted in a pronounced reduction in body weight, highlighting its catabolic actions52,53. Co-administration of HPH partially mitigated this effect, allowing recovery after treatment discontinuation. These results indicate that HPH not only sustains the analgesic efficacy or dexamethasone but also improve tolerability, which may reflect a partial attenuation of treatment-related adverse effects. Nonetheless, several limitations should be acknowledged. First, we tested the treatment only in a single model of acute capsaicin-induced hyperalgesia, which may limit the generalizability of our findings to chronic inflammatory or neuropathic pain conditions. Second, the evaluation of side effects was incomplete. Apart from body weight, we did not assess other corticosteroid-related toxicities such as hyperglycemia, osteoporosis, or immune suppression. Comprehensive toxicity studies will be required to establish the long-term safety of HPH. Third, the involvement of cytokine modulation was not directly examined in this study. Given that capsaicin-induced hyperalgesia is associated with neuroinflammatory processes, the analgesic effect of HPH may be partly related to modulation of such pathways. However, further studies are needed to clarify this mechanism. Conclusion Our findings demonstrate that HPH could suppress both primary and secondary hyperalgesia induced by capsaicin, reflecting the inhibition of peripheral and central sensitization, respectively. Its combination with dexamethasone provides effective analgesia while reducing corticosteroid-associated body weight loss. These results highlight HPH as a promising adjunct for corticosteroid-based pain management. Importantly, the ability of HPH to sustain analgesic efficacy while minimizing systemic side effects implies potential value in optimizing current therapeutic strategies.